|Bid||484.23 x 800|
|Ask||485.14 x 1800|
|Day's range||466.90 - 484.38|
|52-week range||403.00 - 560.00|
|Beta (5Y monthly)||0.46|
|PE ratio (TTM)||25.35|
|Earnings date||21 Feb 2022 - 25 Feb 2022|
|Forward dividend & yield||1.44 (0.31%)|
|Ex-dividend date||12 Nov 2021|
|1y target est||576.00|
Investors continue to be optimistic about Abiomed (ABMD) due to its Impella product line strength.
BD's (BDX) acquisition of Venclose is expected to deliver a patient-centric approach to care.
Investors are optimistic about CVS Health (CVS) on strong third-quarter 2021 results and raised full-year outlook.